Alimentary Pharmacology & Therapeutics · 2012 · 69 citations · 39 references
MedicineOncologyPathologyGastroenterologyGastrointestinal OncologyNeoplasiaGastric CancerGastric DiseasesGastric DisordersGastrointestinal NeoplasmsGastrointestinal PathologyCase-control Study DesignGastric Cancer PrevalenceGastric Intestinal MetaplasiaGastric PathologyGastric Premalignant LesionsGastrointestinal TumorsHelicobacter Pylori InfectionPremalignant Change
BACKGROUND: First-degree relatives (FDRs) of early-onset gastric carcinoma (EOGC) patients are at increased risk of cancer development. OLGA/OLGIM (Operative Link on Gastritis/Intestinal Metaplasia Assessment) classifications have been proposed for the identification of individuals at high risk of gastric cancer development. AIM: To estimate the prevalence and severity of premalignant conditions and lesions in FDRs of EOGC patients. METHODS: A case-control study was conducted encompassing 103 FDRs of EOGC patients (cases) and 101 age- and gender-matched controls, all submitted to upper GI endoscopy and OLGA and OLGIM used for staging as well as modified versions with exclusion of the biopsies from incisura angularis in the analysis. RESULTS: Helicobacter pylori infection was present in 82% of cases (P = 0.001). Atrophy was present in 70% of cases (OLGA stages I-IV). High-risk stages (III-IV) were identified only in cases (19%) (P < 0.001). Dysplasia was diagnosed only in cases (n = 7, P = 0.007). The application of OLGIM, modified OLGA and modified OLGIM classifications led to downgrade of stages in comparison with the original OLGA classification (27%, 15% and 30% respectively). In all classification systems, dysplastic lesions clustered (86%) in high-risk stages. CONCLUSIONS: FDRs of EOGC patients have, even at young ages, a high prevalence of H. pylori infection, high-risk OLGA and OLGIM stages and dysplasia. These patients should undergo accurate endoscopic observation with at least four biopsies in antrum and corpus to allow adequate staging and follow-up of premalignant conditions and lesions scored in high-risk stages, in accordance with international guidelines recently proposed.
39
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
A. J. Zuckerman · Journal of Clinical Pathology · 1995 · 8.8K citations · Full text
Medicine, Oncology, Toxicology +14
Farin Kamangar, Graça M. Dores, William F. Anderson · Journal of Clinical Oncology · 2006 · 3.5K citations
Hans F. A. Vasen, Peter H. Watson, Jukka‐Pekka Mecklin et al. · Gastroenterology · 1999 · 2.5K citations · Full text
Life Sciences, Genetics, Oncology +17
Mário Dinis‐Ribeiro, Miguel Areia, Annemarie de Vries et al. · Endoscopy · 2011 · 678 citations · Full text
Medicine, Pathology, Early Detection +14